the trouble is that the burden is wrongly on consumers to file complaints with the FDA if they find that their generic medications are not performing in the way

the trouble is that the burden is wrongly on consumers to file complaints with the FDA if they find that their generic medications are not performing in the way that they should. based on my experience inside the biotech/biopharma industry within several different roles, i think that ideally the FDA would be terrorizing the pharma companies producing generics such that each new manufacturing lot of medications would be tested for bioequivalence in small cohorts of patients before hitting the market. of course, this will never happen because it would be expensive and time consuming for manufacturers of generics, who rely on volume to make a profit (traditionally -- i know this is changing as they are currently raising prices like wild). so, consumers get the shaft and nothing is done because the perfect solution has the imperfection of reducing revenues. it's a tough problem, though. i'm fairly certain that doctors know that you get what you pay for with many generics -- but i'm also fairly certain that doctors understand not everyone can afford brand name medication.